SG11202013107QA - Fc binding fragments comprising a cd137 antigen-binding site - Google Patents

Fc binding fragments comprising a cd137 antigen-binding site

Info

Publication number
SG11202013107QA
SG11202013107QA SG11202013107QA SG11202013107QA SG11202013107QA SG 11202013107Q A SG11202013107Q A SG 11202013107QA SG 11202013107Q A SG11202013107Q A SG 11202013107QA SG 11202013107Q A SG11202013107Q A SG 11202013107QA SG 11202013107Q A SG11202013107Q A SG 11202013107QA
Authority
SG
Singapore
Prior art keywords
binding
antigen
fragments
binding site
site
Prior art date
Application number
SG11202013107QA
Inventor
Matthew Lakins
Jose Munoz-Olaya
Sarka Pechouckova
Mihriban Tuna
Original Assignee
F Star Beta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Beta Ltd filed Critical F Star Beta Ltd
Publication of SG11202013107QA publication Critical patent/SG11202013107QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
SG11202013107QA 2018-07-12 2019-07-12 Fc binding fragments comprising a cd137 antigen-binding site SG11202013107QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1811408.2A GB201811408D0 (en) 2018-07-12 2018-07-12 CD137 Binding Molecules
PCT/EP2019/068803 WO2020011972A1 (en) 2018-07-12 2019-07-12 Fc binding fragments comprising cd137 antigne binding side

Publications (1)

Publication Number Publication Date
SG11202013107QA true SG11202013107QA (en) 2021-01-28

Family

ID=63273199

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202013107QA SG11202013107QA (en) 2018-07-12 2019-07-12 Fc binding fragments comprising a cd137 antigen-binding site

Country Status (14)

Country Link
US (1) US20220119539A9 (en)
EP (1) EP3820514A1 (en)
JP (2) JP7410115B2 (en)
KR (1) KR20210030406A (en)
CN (1) CN112739377A (en)
AU (1) AU2019303032A1 (en)
BR (1) BR112021000397A2 (en)
CA (1) CA3105994A1 (en)
GB (1) GB201811408D0 (en)
IL (1) IL280005A (en)
MX (1) MX2021000387A (en)
SG (1) SG11202013107QA (en)
TW (1) TW202019475A (en)
WO (1) WO2020011972A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
MA52366A (en) 2018-04-25 2021-03-03 Prometheus Biosciences Inc OPTIMIZED ANTI-TL1A ANTIBODIES
KR20220103721A (en) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
EP0658113B1 (en) 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
NZ282536A (en) 1994-03-01 1998-07-28 Ludwig Inst Cancer Res Nucleic acid molecule useful as a primer in determining expression of a mage tumour rejections antigen precursor
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101098891B (en) 2005-01-05 2014-05-21 F-星生物技术研究与开发有限公司 Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US8921279B2 (en) * 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
PL2215121T3 (en) 2007-11-26 2016-07-29 Bayer Ip Gmbh Anti-mesothelin antibodies and uses therefor
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
DK3354661T3 (en) 2015-09-22 2020-07-06 Dingfu Biotarget Co Ltd Completely human antibody to human CD137 and its use
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology

Also Published As

Publication number Publication date
JP2021524270A (en) 2021-09-13
WO2020011972A9 (en) 2020-02-20
TW202019475A (en) 2020-06-01
US20210277134A1 (en) 2021-09-09
WO2020011972A1 (en) 2020-01-16
EP3820514A1 (en) 2021-05-19
MX2021000387A (en) 2021-05-27
BR112021000397A2 (en) 2021-04-06
US20220119539A9 (en) 2022-04-21
JP2024019419A (en) 2024-02-09
CA3105994A1 (en) 2020-01-16
GB201811408D0 (en) 2018-08-29
CN112739377A (en) 2021-04-30
JP7410115B2 (en) 2024-01-09
AU2019303032A1 (en) 2021-03-04
KR20210030406A (en) 2021-03-17
IL280005A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
IL280005A (en) Fc binding fragments comprising a cd137 antigen-binding site
IL283811A (en) Tumor-targeted agonistic cd28 antigen binding molecules
IL276730A (en) Gan-cnn for mhc peptide binding prediction
SG11202011518VA (en) Self-propelled robot for rebar binding
IL286603A (en) Treatment employing anti-il-13r antibody or binding fragment thereof
ZA202202420B (en) Recovery over sidelink
IL288557A (en) Antibody cleavage site binding molecule
DK3130407T3 (en) PROCEDURE FOR BINDING A PIEZOELECTRIC ULTRASOUND TRANSDUCER
IL270908A (en) Adamts binding immunoglobulins
IL284926A (en) Cd3-specific binding molecules
GB2523399B (en) A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
EP3848535A4 (en) Binding machine
EP3811131A4 (en) Overlapping fiber gratings
EP3587707C0 (en) Binding machine
IL304317A (en) Tgf-beta-rii binding proteins
GB2582305B (en) Bend restrictor
EP3848292A4 (en) Binding machine
EP3848537A4 (en) Binding machine
LT3587708T (en) Binding machine
EP4051316A4 (en) Antibodies for binding plasminogen
GB201918733D0 (en) Discrete Optimisation
EP3848293A4 (en) Binding machine
EP3848534A4 (en) Binding machine
EP3848533A4 (en) Binding machine
ZA201907979B (en) Method for binding a bundle of leaves